Tonbo,

Here are the answers I can provide to your questions

Q. Fall 2007..Has the Filing of the IND taken place??
Not Yet, but I understand it will be very soon

Q. Winter 2007..Was this fulfilled by the recent PLRS announcement of
the application for PLX cells in treatment of stroke??
No.  Pluristem has not chosen which indication it will pursue next, after the bone marrow transplant market.  From what I was told, they have excellent results for their stroke animal testing, but there are several other excellent indications. Pluristem will have to consider such things as length of trials, market size and potential competition, among many other issues.

Q. Winter 2007..Have there already been animal studies initiated for the
stroke treatment indication? Is this info the info coming out of the
German Congress?
YES – the press release regarding the Fraunhofer animal study and the presentation at the "3rd World Congress on Regenerative Medicine" in Leipzig, Germany was regarding using PLX cells as a potential therapy to treat stroke victims.  The German Congress?  Your are kidding, right?

Q. Did someone <the FDA??> ask for additional animal studies??
NO! The studies for filing the IND with the FDA for bone marrow transplants are done.